BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38478102)

  • 1. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
    Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
    World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
    Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
    BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score-matched analysis.
    Deivasigamani S; Orabi H; El-Shafei A; Adams ES; Kotamarti S; Aminsharifi A; Davis L; Wu Y; J SJ; Polascik TJ
    Prostate; 2023 Oct; 83(14):1373-1386. PubMed ID: 37469120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer.
    Williams AK; Martínez CH; Lu C; Ng CK; Pautler SE; Chin JL
    Eur Urol; 2011 Sep; 60(3):405-10. PubMed ID: 21185115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy.
    Spiess PE; Lee AK; Leibovici D; Wang X; Do KA; Pisters LL
    Cancer; 2006 Jul; 107(2):275-80. PubMed ID: 16770783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer.
    Ahmad I; Kalna G; Ismail M; Birrell F; Asterling S; McCartney E; Greene D; Davies J; Leung HY
    PLoS One; 2013; 8(8):e69243. PubMed ID: 23950886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage Cryoablation for Recurrent Prostate Cancer Following Primary External Beam Radiotherapy or Primary Cryotherapy: A Propensity Score Matched Analysis of Mid-term Oncologic and Functional Outcomes.
    Campbell SP; Deivasigamani S; Arcot R; Adams ES; Orabi H; Elshafei A; Tan WP; Davis L; Wu Y; Chang A; Jones JS; Polascik TJ
    Clin Genitourin Cancer; 2023 Oct; 21(5):555-562. PubMed ID: 37438234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.
    Nair SM; Peters M; Kurver P; Lavi A; Verhoeff JJC; van der Voort van Zyp JRN; van Son MJ; Chin JL
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):186-192. PubMed ID: 32814843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy.
    Zhenhao Z; Xiaofeng C; Hao J; Ming Y; Hongtao Z; Wenrui H; Cheng Z; Xiaochen Z; Gongxian W
    Cancer Med; 2022 Sep; 11(17):3251-3259. PubMed ID: 35307955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operative and Midterm Oncological Outcome of Focal Salvage Cryotherapy for Localized Prostate Cancer.
    Vestris PG; Giwerc A; Hennequin C; Goujon A; Meria P; Verine J; Desgrandchamps F; de Kerviler E; Mongiat-Artus P; Masson-Lecomte A
    Urol Int; 2022; 106(9):897-902. PubMed ID: 34781287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
    Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
    Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
    BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
    Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
    J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience.
    de la Taille A; Hayek O; Benson MC; Bagiella E; Olsson CA; Fatal M; Katz AE
    Urology; 2000 Jan; 55(1):79-84. PubMed ID: 10654899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence.
    De La Taille A; Benson MC; Bagiella E; Burchardt M; Shabsigh A; Olsson CA; Katz AE
    BJU Int; 2000 Feb; 85(3):281-6. PubMed ID: 10671882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients.
    Kongnyuy M; Berg CJ; Kosinski KE; Habibian DJ; Schiff JT; Corcoran AT; Katz AE
    Int J Hyperthermia; 2017 Nov; 33(7):810-813. PubMed ID: 28540788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
    J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
    Morris LM; Izard MA; Wan WY
    Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.